Archford Capital Strategies LLC Purchases 511 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Archford Capital Strategies LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.5% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 11,968 shares of the medical research company’s stock after buying an additional 511 shares during the quarter. Archford Capital Strategies LLC’s holdings in IQVIA were worth $2,352,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. FMR LLC raised its stake in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA during the 3rd quarter valued at approximately $147,683,000. JPMorgan Chase & Co. increased its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in shares of IQVIA by 285.1% during the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after buying an additional 198,808 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on IQV. The Goldman Sachs Group dropped their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft cut their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. BTIG Research decreased their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Finally, Stephens began coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Price Performance

NYSE:IQV opened at $204.54 on Friday. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a market capitalization of $37.12 billion, a price-to-earnings ratio of 26.84, a PEG ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The business has a 50 day simple moving average of $199.71 and a 200-day simple moving average of $221.06.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.